Asset Details
Do you wish to reserve the book?
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
Do you wish to request the book?
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
2019
Overview
Background
Dynamic
N
6
-methyladenosine (m
6
A) modification was previously identified as a ubiquitous post-transcriptional regulation that affected mRNA homeostasis. However, the m
6
A-related epitranscriptomic alterations and functions remain elusive in human cancer. Here we aim to identify the profile and outcome of m
6
A-methylation in hepatocellular carcinoma (HCC).
Results
Using liquid chromatography-tandem mass spectrometry and m
6
A-immunoprecipitation in combination with high-throughput sequencing, we determined the m
6
A-mRNA levels in human HCC. Human HCC exhibited a characteristic gain of m
6
A modification in tandem with an increase of mRNA expression, owing to YTH domain family 2 (YTHDF2) reduction. The latter predicted poor classification and prognosis of HCC patients, and highly correlated with HCC m
6
A landscape. YTHDF2 silenced in human HCC cells or ablated in mouse hepatocytes provoked inflammation, vascular reconstruction and metastatic progression. Mechanistically, YTHDF2 processed the decay of m
6
A-containing interleukin 11 (IL11) and serpin family E member 2 (SERPINE2) mRNAs, which were responsible for the inflammation-mediated malignancy and disruption of vascular normalization. Reciprocally, YTHDF2 transcription succumbed to hypoxia-inducible factor-2α (HIF-2α). Administration of a HIF-2α antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer.
Conclusion
Our results have characterized the m
6
A-mRNA landscape in human HCC and revealed YTHDF2 as a molecular ‘rheostat’ in epitranscriptome and cancer progression.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
Adenosine - analogs & derivatives
/ Animals
/ Biomedical and Life Sciences
/ Cancer
/ Carcinoma, Hepatocellular - etiology
/ Carcinoma, Hepatocellular - pathology
/ HCC
/ Humans
/ IL-11
/ Inflammation - complications
/ Liver
/ m6A
/ Mice
/ Neovascularization, Pathologic - genetics
/ Oncology
/ RNA
/ RNA-Binding Proteins - genetics
/ RNA-Binding Proteins - metabolism
/ YTHDF2
